Negative Pledge Covenants in Pharmaceutical Credit Agreements
Disclaimer: This article is for informational purposes only and does not constitute legal, financial, or investment advice. The author is
The Weekly Term Sheet (43)
Disclaimer: This article is for informational purposes only and does not constitute legal, financial, or investment advice. The author is
Volatility Laundering: Smoothing Out Risk or Sweeping It Under the Rug?
A Calm Surface Hiding Choppy Seas
Imagine a portfolio that glides through market turmoil with uncanny smoothness, scarcely registering a
Fund of the week: Nvidia's NVentures
Disclaimer: This article is for informational purposes only and does not constitute legal, financial, or investment advice. The author is
Company of the Week: Lila Sciences – A Red and Blue Team Analysis
Introduction
Lila Sciences is a cutting-edge startup aiming to revolutionize scientific research through artificial intelligence and automation. Founded in 2023
Anthropic's Claude in Life Sciences: Accelerating Biotech and Healthcare R&D
Anthropic launched "Claude for Life Sciences" in October 2025, introducing new AI capabilities tailored to biotechnology and pharmaceutical
The Rise of Revenue-Based Financing in Biotech and Digital Therapeutics
Disclaimer: This article is for informational purposes only and does not constitute legal, financial, or investment advice. The author is
Royalty Deferral Structures in Pharmaceutical and Biotechnology Financing
Introduction
Royalty deferral structures represent sophisticated financing and licensing arrangements that fundamentally alter the timing and conditionality of royalty payments
The Weekly Term Sheet (42)
Biotech and Pharmaceutical Deals: October 13-19, 2025
The week of October 13-19, 2025 marked one of the most active periods
The great divide: Why royalty financing conquered North America but struggles everywhere else
Royalty financing in biotech and healthcare has exploded into a $5-6 billion annual market in North America, with transactions growing
